The dawn of targeted therapy for primary myelofibrosis: Opportunities and challenges

Ruben A. Mesa

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)883-886
Number of pages4
JournalLeukemia Research
Volume31
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Myeloproliferative Disorders
Primary Myelofibrosis
Antineoplastic Agents
Vascular Endothelial Growth Factor A
Therapeutics
vatalanib

Keywords

  • JAK2
  • Myeloproliferative disorders
  • Primary myelofibrosis
  • PTK 787
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The dawn of targeted therapy for primary myelofibrosis : Opportunities and challenges. / Mesa, Ruben A.

In: Leukemia Research, Vol. 31, No. 7, 07.2007, p. 883-886.

Research output: Contribution to journalArticle

@article{71e71bbc559743a399c16c65b2cc19d0,
title = "The dawn of targeted therapy for primary myelofibrosis: Opportunities and challenges",
keywords = "JAK2, Myeloproliferative disorders, Primary myelofibrosis, PTK 787, VEGF",
author = "Mesa, {Ruben A.}",
year = "2007",
month = "7",
doi = "10.1016/j.leukres.2007.01.001",
language = "English (US)",
volume = "31",
pages = "883--886",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - The dawn of targeted therapy for primary myelofibrosis

T2 - Opportunities and challenges

AU - Mesa, Ruben A.

PY - 2007/7

Y1 - 2007/7

KW - JAK2

KW - Myeloproliferative disorders

KW - Primary myelofibrosis

KW - PTK 787

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=34249786248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249786248&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.01.001

DO - 10.1016/j.leukres.2007.01.001

M3 - Article

C2 - 17303238

AN - SCOPUS:34249786248

VL - 31

SP - 883

EP - 886

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -